瑞普利蒙生物
REPL
10.86
-0.89
-7.57%
瑞普利蒙生物
US · REPL
#3130 按市值排名
上市于 2018
10.86
-0.89
-7.57%
实时 - 追踪5344个代码 - 心跳于387秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例下降了10.1个百分点。
机构持股
- 机构持股比例
- 104.24% -10.06pp
- 机构数量
- 228 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund46.33%
Mutual Fund42.96%
Public Company7.62%
Private Company3.78%
VC/PE Fund3.00%
Individual/Insider1.59%
Insurance Company0.33%
Government Pension Fund0.17%
主要股东 截至 2026-08-09
Baker Bros. Advisors LP
11.72% · 11.05M 股
BlackRock
9.51% · 8.96M 股
RTW Investments, LP
7.87% · 7.41M 股
Ridgeback Capital Management LLC
7.76% · 7.31M 股
Montanova Capital, LLC
7.01% · 6.61M 股
State Street Global Advisors
4.71% · 4.44M 股
The Goldman Sachs Group, Inc.
4.63% · 4.36M 股
Boxer Capital Management, LLC
4.23% · 3.98M 股
Vanguard Capital Management, LLC
3.59% · 3.39M 股
Forbion Capital Partners B.V.
2.98% · 2.81M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 26次买入 · 24次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Baker Bros. Advisors LP | -- | 11.72% |
| Philip Astley-Sparke | Chief Executive Officer | 1.36% |
| Sushil Patel | Chief Strategy Officer | 0.09% |
| Konstantinos Xynos | Chief Medical Officer | 0.05% |
| Emily Hill | Chief Financial Officer | 0.04% |
| Christopher Sarchi | Chief Commercial Officer | 0.03% |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer | 0.02% |
| Joseph Slattery | Independent Director | 0.01% |
| Julian Baker | -- | -- |
| Michael Goller | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-19 | Philip Astley-Sparke | Chief Executive Officer | Other Disposition | -50,000 | -- |
| 2026-08-16 | Emily Hill | Chief Financial Officer | Open Market Disposition | -9,256 | $14.28 |
| 2026-08-10 | Baker Bros. Advisors LP | -- | Open Market Derivative Acquisiti | +2,736,340 | $0.00 |
| 2026-08-09 | Emily Hill | Chief Financial Officer | Open Market Disposition | -11,448 | $12.97 |
| 2026-08-09 | Sushil Patel | Chief Strategy Officer | Open Market Disposition | -39,341 | $12.97 |
| 2026-08-09 | Andrew Schwendenman | Chief Accounting Officer & Treasurer | Open Market Disposition | -7,632 | $12.97 |
| 2026-08-09 | Konstantinos Xynos | Chief Medical Officer | Open Market Disposition | -11,447 | $12.97 |
| 2026-05-31 | Christopher Sarchi | Chief Commercial Officer | Automatic Disposition | -12,000 | $9.24 |
| 2026-05-17 | Philip Astley-Sparke | Chief Executive Officer | Open Market Disposition | -17,657 | $5.08 |
| 2026-05-17 | Emily Hill | Chief Financial Officer | Open Market Disposition | -7,812 | $5.08 |
| 2026-05-17 | Sushil Patel | Chief Strategy Officer | Open Market Disposition | -37,324 | $5.08 |
| 2026-05-17 | Christopher Sarchi | Chief Commercial Officer | Open Market Disposition | -8,626 | $5.08 |
| 2026-05-17 | Andrew Schwendenman | Chief Accounting Officer & Treasurer | Open Market Disposition | -7,894 | $5.08 |
| 2026-05-17 | Konstantinos Xynos | Chief Medical Officer | Open Market Disposition | -14,023 | $5.08 |
| 2026-04-01 | Christopher Sarchi | Chief Commercial Officer | Automatic Disposition | -6,500 | $8.01 |
| 2026-03-31 | Joseph Slattery | Independent Director | Other Derivative Acquisition | +44,500 | $7.61 |
| 2026-03-31 | Julian Baker | -- | Other Derivative Acquisition | +89,000 | $7.61 |
| 2026-03-31 | Philip Astley-Sparke | Chief Executive Officer | Other Acquisition | +50,000 | -- |
| 2026-03-31 | Philip Astley-Sparke | Chief Executive Officer | Other Derivative Acquisition | +75,000 | $7.61 |
| 2026-03-31 | Paolo Pucci | Independent Director | Other Derivative Acquisition | +44,500 | $7.61 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:17 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
瑞普利蒙生物 讨论区 0 条评论